Cyclacel Pharmaceuticals, Inc. (CYCC)
-NasdaqGM | Prev Close: | 2.99 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.73 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.91 - 8.18 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 181,073 |
|---|
| Market Cap: | 32.53M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.54 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, May 22)
- Cyclacel Pharmaceuticals Announces Closing of Underwritten OfferingGlobeNewswire(Tue, May 21)
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 21)
- CYCLACEL PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Cyclacel Announces New Stock Issueat Motley Fool(Thu, May 16)
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, FinanciaEDGAR Online(Thu, May 16)
- Cyclacel Pharmaceuticals Announces $20 Million Underwritten OfferingGlobeNewswire(Thu, May 16)
- Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswire(Wed, May 15)
- Cyclacel Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 13)
- Cyclacel Reports First Quarter 2013 Financial ResultsGlobeNewswire(Mon, May 13)
- CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementEDGAR Online(Mon, May 13)
- Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial ResultsGlobeNewswire(Fri, May 10)
- Cyclacel Pharmaceuticals' Convertible Exchangeable Preferred Stock Shares Cross 8% Yield Markat Forbes(Mon, May 6)
- Cyclacel Pharmaceuticals update Phase 2 survival data of sapacitabine for MDStheflyonthewall.com(Tue, Apr 30)
- Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDSGlobeNewswire(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 115.78 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | N/A |
|---|
| Quarterly EPS Est
(Sep-12)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases.
View More 
0.52%